Genentech

All Photos Twitter.com
Congratulations to our VP and Chief Diversity Officer, Quita Highsmith for her recognition as LEAD360’s Executive of the Year! Read more about Quita’s bold leadership and efforts to advance equity in healthcare and beyond: bit.ly/3DVs41N
#Breaking: We're presenting new data at #ASH22 on multiple blood diseases that reinforce our commitment to redefining treatment paradigms and improve standards of care for patients. Learn more: gene.com/media/press-re…
We were named one of @ScienceMagazine’s Top 20 Employers! We owe this achievement for 21 years in a row to our employees’ leadership in tackling challenging scientific problems and dedication to creating a vibrant, inclusive company culture. #SCTopEmployer bit.ly/3NaLdzT
#Breaking: Today we announced the first and only #bispecific antibody for the eye improved vision for people living with two types of retinal vein occlusion (RVO). Learn more about the positive topline results from two global trials: gene.com/media/press-re… @GenentechEye
We’re sharing new data that reinforce important disease progression and economic benefits of our #multiplesclerosis (MS) therapy, as well as findings from the largest sample of pregnancy outcomes for an anti-CD20 therapy. Learn more: gene.com/media/press-re…
ICYMI: Our most recent Portraits in Science features medicinal chemist, Gina Wang, who is leading drug discovery efforts in oncology, including developing new treatments for women with breast cancer who may not benefit from existing medicines. Read more:
#Breaking: We’re presenting new data at #ECTRIMS2022 that further advance the scientific understanding of #multiplesclerosis (MS) and neuromyelitis optica spectrum disorder (#NMOSD). Learn more: gene.com/media/press-re…
ICYMI: At #WMS2022 we presented two-year data on our spinal muscular atrophy (#SMA) treatment in people previously treated with other SMA-targeting therapies. Read more: bit.ly/3eEy7xU
In our latest Portraits in Science, our own Gina Wang shares how her team is taking novel approaches to investigating new cancer treatments. Learn how she’s using small molecules to reimagine cancer immunotherapy: bit.ly/3rXRzZi
During #WMS2022, we presented new two-year data on our spinal muscular atrophy (SMA) treatment in people with previously-treated #SMA. Read more: gene.com/media/press-re…
We’re working to bring #immunotherapy to earlier stages of liver #cancer to help prevent recurrence. For people at higher risk, liver screening is a key step for early diagnosis, when cancer is most treatable. Read more: AgainstLiverCancer.com #LiverCancerAwarenessMonth
Congratulations to our own Sandra Milan, VP, Project Team Leadership, Molecular Oncology, for being named one of @SFBusinessTimes Most Influential Women in Business! Read about her leadership in oncology innovation and fostering diversity in science: bit.ly/3rFQdm8
Futurelab+ offers a comprehensive high school curriculum combining the latest scientific concepts with health equity principles & information on the vast range of biotech careers. Learn more from teachers who developed it & check it out for yourself here: bit.ly/3rySAH8
We’re collaborating with @RecursionPharma and @Roche to build maps of human cellular biology, combining their tech platform with our data generation and ML capabilities. Learn how this partnership will bring us closer to developing new medicines: bit.ly/3SODskG
One therapeutic strategy to treat a range of diseases is to design molecules that degrade specific proteins. In @Nature, our scientists describe a new antibody-based approach for tumor-specific protein degradation (PROTABs). Read more: go.nature.com/3UNYkdy
We celebrate this important moment of positivity in Alzheimer’s disease research and congratulate our colleagues, friends and scientific peers at Eisai who have been driving the research that led to positive topline results on amyloid-targeted therapies.
#Poll: What do you find to be the most important element of a standards-aligned high school biotech curriculum? Vote below & check out our new Futurelab+ program that offers all of these topics in one comprehensive high school curriculum: bit.ly/3SqRPM6
Fibroblasts are key structural cells & some types are associated with cancer progression. In @Nature, @akshayk25, @SorenMuller1, @TurleyLabGNE & team found that depleting a subset of these cells in tumors can improve responsiveness to cancer immunotherapy: go.nature.com/3RmlnJm
Congrats to our very own Vishva Dixit, VP of Early Discovery Research, a recipient of the 2022 William B. Coley Award for Distinguished Research in Basic and Tumor Immunology from the @CancerResearch Institute! bit.ly/3E1uD2B
Did you know Alzheimer’s develops slowly and may take up to 25 years for symptoms to become noticeable? Learn more about this complex disease by testing your knowledge. #WorldAlzMonth bit.ly/3rauzWM
Today we launched Futurelab+, a $10M expansion to scale the impact of our Futurelab STEM education program nationwide. See how we & our partners designed an open-source curriculum to introduce students from diverse backgrounds to STEM concepts & careers: bit.ly/3LMvbew
Discussions at #ClimateWeekNYC underscore the urgent need for action. We’re excited to share our latest action - participation in the U.S. Dept. of @ENERGY’s Better Climate Challenge! Learn more about how we’re reducing our environmental footprint: bit.ly/3UvKhJm
When it comes to how Alzheimer’s manifests in the brain, many factors are at play. Learn more about the disease and the research underway to better understand it: bit.ly/3BWuQCT #WorldAlzMonth
Our partners help us deepen our understanding of human biology with their unique expertise. We've joined forces with @RecursionPharma to combine our data and ML capabilities with their technology platform to produce maps of human cellular biology that will advance new medicines. twitter.com/RecursionPharm…
We’re helping facilitate access to @TheIHI’s Pursuing Equity initiative for organizations committed to advancing equity & justice in health. Now, for the first time, engaging will be free for all participating groups. Learn more: bit.ly/3Ls6ELN twitter.com/TheIHI/status/…
Join our @AtlanticLIVE panel discussion on 9/21 at 6:30am PT as we connect with members of the neuroscience community, @mssociety, LAMDA & disability advocates, Shane & Hannah Burcaw, to discuss accessibility, visibility & DEI in neuroscience. bit.ly/3Dqf04C #TAF22
Research at #ESMO22 highlights our focus on unlocking the potential of #immunotherapy to transform cancer care. Hear more from our leadership: bit.ly/3xgPmv9
We’re in NYC at the #DoubleTakeShow prelude to #NYFW! Tune in to the livestream to watch the show participants with spinal muscular atrophy (SMA) strut down the runway and demonstrate what inclusivity can look like in the fashion industry. youtube.com/watch?v=yMXQws…
We’re excited to join the #oncology community at #ESMO22 this week. Learn more about our work to discover innovative medicines and personalize #cancer care for all patients: bit.ly/3D68uj9
Thank you @FortuneMagazine for naming us one of the Best Workplaces in Biopharma! We owe this recognition to all our employees for fostering a culture where groundbreaking science can thrive. bit.ly/3ex4L47
The COVID-19 pandemic has highlighted the urgent need to improve our country's response to a public health crisis. There are five actions we can take today to build on the learnings from the pandemic to develop solutions and better prepare for the future. bit.ly/3Rng657
We’ve partnered with the spinal muscular atrophy (SMA) community & clothing designers from @OpenStyleLab for a fashion show prelude to #NYFW called #DoubleTakeShow! Watch the livestream of the event on Sept 8 here: bit.ly/3CrOnMe
We’ve been recognized as one of @people's 100 Companies That Care for the 2nd year in a row! With our giving, we’re advancing efforts to diversify the STEM workforce, address health inequities & help our communities thrive. Read more: bit.ly/3pXQlwl
In @Cell_Metabolism, our scientists found proteins associated with liver fibrosis progression, a predictor of liver-related complications in people with chronic liver disease. These findings also help identify a compelling drug target for future therapies:bit.ly/3RntfuU
Using these advanced microscopy techniques, our scientists can better understand the biological interactions between cancer and our immune systems and uncover potential avenues for developing new immunotherapies. Learn more: bit.ly/3QJkiMp
After the cancer cell evades the attack, another T cell comes from the top and delivers the second hit necessary to kill the cancer cell. It takes a certain amount of toxin to kill cancer cells, and multiple T cells may be needed to get the job done.
This video by @RitterLab shows an immune cell called a T cell (purple) approaching and attaching to a cancer cell (teal). The T cell tries to kill the cancer cell by secreting a toxin (red wave), but the cancer cell survives. Follow this thread to see how this battle ends. ⬇️
Our scientists are using cutting-edge microscopy techniques to uncover discoveries around how cancer and the immune system interact. Learn how the power to “see” biology in action can deepen our understanding of complex diseases and advance new treatments: bit.ly/3CugXMM
Health equity is a major problem in healthcare research, and stakeholders across the ecosystem are demanding better representation. Listen to our two-part #podcast special on why we must pursue more inclusive research in clinical trials here: bit.ly/3T95p7N
Oligodendrocyte cells provide support and insulation for neurons in the brain. In @CellReports, our scientists identified how these cells play a role in neurodegenerative diseases like Alzheimer’s disease to help develop future treatments: bit.ly/3R1dolm
We were also honored to be joined by Deputy Mayor of San Mateo @DianePapan, Vice Mayor of Millbrae @GinaPapan, SSF City Councilmembers Mark Addiego & @EddieFloresSSF, Sr. Deputy Director of GOBiz Aracely Campa Ramirez & Saúl Miranda from @SenJoshBecker’s office at this event!
Special thank you to Lt. Governor @EleniForCA, Speaker pro Tem @kevinmullin, SSF Mayor @MarkNagales and Vice Mayor Flor Nicolas for helping us officially open our new facility as we usher in the future of innovative and sustainable biologics manufacturing.
Today we’re cutting the ribbon on our Clinical Supply Center, our flagship small-batch biologics facility at the forefront of next-generation manufacturing and environmentally sustainable production. Learn more: bit.ly/3KaVWJ8
ICYMI: In our latest #podcast episode, Nicole Richie and Jenn Pangilinan expanded on diversity in clinical trials and how current study criteria could be reconsidered to better represent patient populations in studies. Check out S4E07 here: bit.ly/3A4hzpG
It’s imperative that we improve diversity in clinical trials in order to treat all populations. In our latest #podcast episode, Nicole Richie & Jenn Pangilinan discuss the importance of addressing trial challenges and broadening representation. Listen: bit.ly/3JWI3hz
Breaking: The @US_FDA accepted the supplemental Biologics License Application for our first-in-class antibody-drug conjugate to treat adults with previously untreated diffuse large B-cell lymphoma (#DLBCL), an aggressive form of #lymphoma. Learn more: gene.com/media/press-re…
This week we're dropping the next episode of our two-part #podcast series on inclusive research. Tune in to S4E07, part of Roche's Life Talk series that focuses on inspiring conversations to find life-changing solutions. bit.ly/3dxPrDV
In order to provide more equitable care for patients, we must think about genomics research, data & people more expansively. Catch up on the latest episode of our #podcast, Two Scientists Walk Into a Bar, which focuses on human genetics, the first in a two-part series.
With flu season nearing, we’re excited to share the @US_FDA approved our #flu medicine to expand its use for the treatment of flu in children ages 5 and older. Learn more: bit.ly/3QHbqqg
#Breaking: The @US_FDA has approved our #flu medicine for the treatment of flu in children ages 5 to 11. This is the first new flu medicine for this age group in 20+ years. gene.com/media/press-re…
Twiends™ uses the Twitter™ API, displays it's logo & trademarks, and is not endorsed or certified by them. These items remain the property of Twitter. We do not sell followers, we only provide display advertising. Bots & fake accounts are not permitted on twiends. © 2009
Grow Your Twitter Free
Want To Grow Your Twitter?
We help other people find and follow you on Twitter.
Key Info:
Started in 2009
Over 6 million signups
Country targeting provided
We never auto tweet to your timeline
We never auto follow others
We actively moderate our community
Please Share
Please upgrade your browser  chrome